RecruitingPhase 1 / Phase 2NCT04977453
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Sponsor: GI Innovation, Inc.
New York, NY · Huntersville, NC
Phase 1/2 Lung Cancer clinical trials
61 recruiting Phase 1/2 lung cancer studies in the US. What trial phases mean
Other phases
RecruitingPhase 1 / Phase 2NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Sponsor: Revolution Medicines, Inc.
Gilbert, AZ · Duarte, CA · Irvine, CA · +26 more sites
RecruitingPhase 1 / Phase 2NCT04959175
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Sponsor: National Cancer Institute (NCI)
Bethesda, MD · Philadelphia, PA
RecruitingPhase 1 / Phase 2NCT06810544
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Sponsor: Tango Therapeutics, Inc.
Scottsdale, AZ · Irvine, CA · Los Angeles, CA · +12 more sites
RecruitingPhase 1 / Phase 2NCT07038343
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Sponsor: Avenzo Therapeutics, Inc.
Gilbert, AZ · Los Angeles, CA · +16 more sites
RecruitingPhase 1 / Phase 2NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Sponsor: Verastem, Inc.
Los Angeles, CA · Baltimore, MD · Boston, MA · +10 more sites
RecruitingPhase 1 / Phase 2NCT05786924
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Sponsor: Institut de Recherches Internationales Servier
Gilbert, AZ · Los Angeles, CA · +18 more sites
RecruitingPhase 1 / Phase 2NCT07070232
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Sponsor: BioNTech SE
Phoenix, AZ · San Francisco, CA · Hartford, CT · +16 more sites
RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Phoenix, AZ · Tucson, AZ · Los Angeles, CA · +34 more sites
RecruitingPhase 1 / Phase 2NCT06780137
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Sponsor: Merck Sharp & Dohme LLC
Aurora, CO · Miami, FL · Chicago, IL · +6 more sites
RecruitingPhase 1 / Phase 2NCT05797168
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Sponsor: AstraZeneca
Duarte, CA · Irvine, CA · La Jolla, CA · +10 more sites
RecruitingPhase 1 / Phase 2NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Sponsor: Obsidian Therapeutics, Inc.
Los Angeles, CA · Stanford, CA · +6 more sites
RecruitingPhase 1 / Phase 2NCT06362252
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Sponsor: Daiichi Sankyo
Birmingham, AL · Phoenix, AZ · Los Angeles, CA · +23 more sites
RecruitingPhase 1 / Phase 2NCT06996782
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Sponsor: AstraZeneca
Phoenix, AZ · Santa Rosa, CA · Jacksonville, FL · +7 more sites
RecruitingPhase 1 / Phase 2NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Sponsor: Radiopharm Theranostics, Ltd
Dothan, AL · Grand Rapids, MI · Omaha, NE · +2 more sites
RecruitingPhase 1 / Phase 2NCT07579221
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Sponsor: Neonc Technologies, Inc.
Beverly Hills, CA · Glendale, CA · Los Angeles, CA · +5 more sites
RecruitingPhase 1 / Phase 2NCT07602855
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Sponsor: GlaxoSmithKline
Los Angeles, CA · Wilson, NC · Canton, OH
RecruitingPhase 1 / Phase 2NCT07278479
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Sponsor: Molecular Partners AG
Tampa, FL · Atlanta, GA · Glen Burnie, MD · +3 more sites
RecruitingPhase 1 / Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Birmingham, AL · Los Angeles, CA · Miami, FL · +15 more sites
RecruitingPhase 1 / Phase 2NCT07629960
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Sponsor: Blueprint Medicines Corporation
Sarasota, FL · Tampa, FL · Baton Rouge, LA · +7 more sites
RecruitingPhase 1 / Phase 2NCT07224152
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT07730021
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Lake Success, NY · Fairfax, VA
RecruitingPhase 1 / Phase 2NCT04486833
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Sponsor: Genprex, Inc.
Los Angeles, CA · Lone Tree, CO · Urbana, IL · +7 more sites
RecruitingPhase 1 / Phase 2NCT04969315
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Sponsor: Portage Biotech
Los Angeles, CA · Houston, TX
RecruitingPhase 1 / Phase 2NCT07564401
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Sponsor: Novartis Pharmaceuticals
Lexington, KY · Houston, TX · Seattle, WA
RecruitingPhase 1 / Phase 2NCT07012031
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Sponsor: National Cancer Institute (NCI)
Sacramento, CA · Tampa, FL · +6 more sites
RecruitingPhase 1 / Phase 2NCT07491497
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Sponsor: TRIANA Biomedicines, Inc.
San Francisco, CA · Aurora, CO · Boston, MA · +11 more sites
RecruitingPhase 1 / Phase 2NCT06043817
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Sponsor: Pierre Fabre Medicament
Duarte, CA · Huntington Beach, CA · Irvine, CA · +6 more sites
RecruitingPhase 1 / Phase 2NCT06567015
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Sponsor: Pierre Fabre Medicament
Nashville, TN · Houston, TX
RecruitingPhase 1 / Phase 2NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Sponsor: BioNTech SE
Phoenix, AZ · Beverly Hills, CA · Los Angeles, CA · +14 more sites
RecruitingPhase 1 / Phase 2NCT04165070
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Sponsor: Merck Sharp & Dohme LLC
Gilbert, AZ · Duarte, CA · San Francisco, CA · +15 more sites
RecruitingPhase 1 / Phase 2NCT03965234
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Sponsor: Roswell Park Cancer Institute
Buffalo, NY
RecruitingPhase 1 / Phase 2NCT04683250
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Sponsor: Taiho Pharmaceutical Co., Ltd.
Orange, CA · Stanford, CA · Boston, MA · +6 more sites
RecruitingPhase 1 / Phase 2NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Sponsor: VM Discovery, Inc.
Scottsdale, AZ
RecruitingPhase 1 / Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Clovis, CA · Los Angeles, CA · Newport Beach, CA · +8 more sites
RecruitingPhase 1 / Phase 2NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
Sacramento, CA · Celebration, FL · Miami, FL · +10 more sites
RecruitingPhase 1 / Phase 2NCT06706076
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Sponsor: BlossomHill Therapeutics
Phoenix, AZ · Irvine, CA · La Jolla, CA · +21 more sites
RecruitingPhase 1 / Phase 2NCT05039632
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Sponsor: Synthekine
Tucson, AZ · Beverly Hills, CA · Fullerton, CA · +30 more sites
RecruitingPhase 1 / Phase 2NCT06088771
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Sponsor: Icahn School of Medicine at Mount Sinai
New York, NY
RecruitingPhase 1 / Phase 2NCT07538804
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Sponsor: Avistone Biotechnology Co., Ltd.
Fairfax, VA
RecruitingPhase 1 / Phase 2NCT06051695
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Sponsor: A2 Biotherapeutics Inc.
Gilbert, AZ · La Jolla, CA · Los Angeles, CA · +9 more sites
RecruitingPhase 1 / Phase 2NCT05361174
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Sponsor: Iovance Biotherapeutics, Inc.
Los Angeles, CA · Miami, FL · Orlando, FL · +8 more sites
RecruitingPhase 1 / Phase 2NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsor: Revolution Medicines, Inc.
Orange, CA · Santa Monica, CA · Tampa, FL · +18 more sites
RecruitingPhase 1 / Phase 2NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Sacramento, CA · Santa Monica, CA · Coral Gables, FL · +12 more sites
RecruitingPhase 1 / Phase 2NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Sponsor: Frontier Medicines Corporation
La Jolla, CA · Orange, CA · San Francisco, CA · +12 more sites
RecruitingPhase 1 / Phase 2NCT06956690
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Sponsor: Hummingbird Bioscience
La Jolla, CA · Indianapolis, IN · Farmington Hills, MI · +2 more sites
RecruitingPhase 1 / Phase 2NCT07030257
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Sponsor: Tasca Therapeutics
Denver, CO · Orlando, FL · Grand Rapids, MI · +10 more sites
RecruitingPhase 1 / Phase 2NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Sponsor: Auricula Biosciences Inc.
Dallas, TX · San Antonio, TX
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.